Read on Twitter
Here's the European Commission's first reaction to the publication of the contract, as per spokesman @ericmamer
"There are a number of plants which are mentioned in the contract we have with AstraZeneca, some of which are located in the United Kingdom...
"There are a number of plants which are mentioned in the contract we have with AstraZeneca, some of which are located in the United Kingdom...
2/ "...and that it is foreseen that these plants will contribute to the efforts of AstraZeneca to deliver doses to the European Union.
"There is absolutely no question for us that this is what the contract specifies.
"There is absolutely no question for us that this is what the contract specifies.
3/ "We are convinced that this applies to the fact when we signed the advanced purchase agreement, the vaccines of course did not yet exist. They were in the process of being developed.
4/ "They could only be delivered subject to a positive recommendation by the EMA...and then the marketing authorisation by the Commission. Therefore, of course, there could be reasons for the company not to be able to deliver vaccines if these conditions were not meant.
5/ "There is another clause, which is manufacturing at risk, which implies that the companies with whom we sign these contracts produce the doses before the authorisation so as to be able to respect the delivery schedules as soon as, and if, authorisation is granted.
6/ "In our mind there is absolutely no doubt that we have a firm commitment with the company, as with all other companies, to deliver doses according to specific schedules, and that the clauses that we have are there to take into account...
7/ ...as is absolutely normal, the fact that at the time the contracts were signed these products did not yet exist."
